$9.1 Billion Poured Into Biotech. Most Startups Didn't See a Dime.

What About Everyone Else?

This is where it gets worrying.

Rare disease startups? Not highlighted among the top-funded categories. Neuroscience? Same story. Antimicrobial companies trying to solve antibiotic resistance (you know, one of the biggest public health threats of our time)? Crickets.

It's not that investors hate these areas. It's that the math has shifted. VCs increasingly want clinical-stage assets with human data and near-term catalysts. They want proof before they write a check, which is rational for any individual investor but potentially disastrous for the ecosystem as a whole.

Think of it like a movie studio that only greenlights sequels. Every individual sequel might be a safer bet. But eventually, you run out of original stories to make sequels from.

The Seed-Stage Squeeze

The numbers paint a clear picture of what analysts are calling a widening startup funding gap.

Seed-stage companies and first-time founders are facing the tightest capital environment in years. The venture market isn't shrinking; it's just concentrating. Bigger checks are going to fewer companies, later in their development. It's like a pyramid where the top keeps growing while the base gets thinner.

That creates a strange paradox. The $9.1 billion total looks healthy, maybe even robust. But the pipeline of brand-new ideas is getting starved. Today's preclinical concept is supposed to become tomorrow's clinical-stage darling. If nobody funds the early stuff, the late-stage pipeline eventually dries up too. It just takes a few years to notice.

Why This Should Scare You (a Little)

Biotech's greatest breakthroughs have often come from unexpected places. CAR-T therapy, GLP-1 drugs for obesity, gene editing: none of these looked like safe bets when they started. They were weird, risky, and hard to pitch to a room full of spreadsheet-loving VCs.

The current funding environment is built to reward the known and punish the unknown. That's fine for generating near-term returns. It's terrible for generating the kind of left-field innovation that actually changes medicine.

Some startups are finding workarounds. Grants, corporate partnerships, milestone-based financings, and venture creation studios can bridge the gap to first-in-human data. But those alternatives are Band-Aids, not solutions. They can't replace the scale of traditional venture capital.

The Bigger Picture

Compare this year to the recent past, and the trend becomes even more obvious. H1 2026's $9.1 billion-plus is the highest first-half total in four years. The market is recovering from the post-2021 downturn. But the recovery is uneven in a way that wasn't true during the boom years.

In Q1 2026 alone, there were 51 Series B and later investments worth $4.5 billion, according to J.P. Morgan data. Meanwhile, seed and early-stage activity has been comparatively muted. The market isn't broken; it's just become extremely selective, favoring companies that have already crossed the riskiest valleys.

So What Happens Next?

If you're building an oncology or autoimmune company with clinical data, congratulations. The funding environment loves you. Ride the wave.

If you're a neuroscience startup, a rare disease company, or an antimicrobial innovator still in preclinical development, the path forward is harder than it's been in years. You'll need creative financing, strategic partnerships, or a data package so compelling that even the most risk-averse VC can't say no.

The $9.1 billion headline is real. The rebound is real. But so is the growing divide between biotech's haves and have-nots. And the startups being left behind today might just be the ones we'll desperately need five or ten years from now.

That's the thing about innovation: you don't always know what you're missing until it's too late.

Sandoz Is Buying Its Biosimilar Future From China

Sandoz just committed up to $322 million to license biosimilars from a Chinese company most people have never heard of. The deal with Shanghai Henlius signals something bigger: China's biologics ecosystem has gone from follower to supplier for the world's largest biosimilar company.